Author information

• ¹Université Paris-Saclay, Gustave Roussy, Villejuif, France. Electronic address: michel.ducreux@gustaveroussy.fr.
• ²Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA; Trinity College Dublin, Dublin, Ireland.
• ³Mayo Clinic Cancer Center, Phoenix.
• ⁴Vanderbilt-Ingram Cancer Center, Nashville, USA.
• ⁵INCLIVA, Biomedical Research Institute, Hospital Clínico Universitario, University of Valencia, Valencia, Spain.
• ⁶Université Paris-Saclay, Gustave Roussy, Villejuif, France.
• ⁷University Medical Center Mainz, Mainz, Germany.
• ⁸BC Cancer/University of British Columbia, Vancouver, Canada.
• ⁹Clinic Favoriten, HPB Center Health Network Vienna and Sigmund Freud University, Medical School, Vienna, Austria.
• ¹⁰University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium.
• ¹¹Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK.
• ¹²Institut du cancer Paris CARPEM, APHP, Georges Pompidou Hospital, Université Paris Cité, Paris, France.
• ¹³Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Universitat de Barcelona, Barcelona; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
• ¹⁴University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany.
• ¹⁵Vall d'Hebron Hospital Campus, Barcelona, Spain; Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain.
• ¹⁶American University of Beirut, Beirut, Lebanon.
• ¹⁷Aichi Cancer Center Hospital, Nagoya, Japan.
• ¹⁸Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
• ¹⁹Instituto Alexander Fleming, Buenos Aires, Argentina.
• ²⁰Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA.
• ²¹Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Tampere University Hospital, University of Tampere, Tampere, Finland.
• ²²Henry Ford Cancer Institute, Departments of Oncology and Pharmacology, Wayne State University, Detroit, USA.
• ²³Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
• ²⁴Instituto Nacional de Cancerologia, Mexico, Mexico.
• ²⁵Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
• ²⁶Ulm University Hospital, Ulm, Germany.
• ²⁷Vall d'Hebron Hospital Campus and Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain.
• ²⁸Hammersmith Hospital, Imperial College London, London, UK.

Abstract

This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.